Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Familial hypercholesterolemia and statins in the COVID-19 era: Mitigating the risk of ischemic stroke

1. Introduction

Usually, when a clinician or a consulting neurologist encounters in clinical work a patient with the inherited form of hypercholesterolemia, i.e., the familial hypercholesterolemia (FH), they associate this disease with athero- and microvascular disease (ASCVD), and their concern is mainly about the risk of premature acute myocardial infarction (AMI). Nevertheless, the clinicians and consulting neurologists need to associate FH patients also with an increased risk of ischemic stroke, particularly regarding FH patients with COVID-19. Currently (April 16, 2021), we still lack data on COVID-19 patients with FH. Accordingly, any treatment suggestion or expert opinion must be based on data obtained from COVID-19 patients in whom the cause of hypercholesterolemia – whether inherited or not – has not been reported [1,2]. In this Letter, we discuss this challenge.

In a very recent analysis, 174 hospitalized patients with COVID-19 and an acute ischemic stroke were pooled from 16 countries, and the disease outcomes were compared with those in patients with an ischemic stroke but without COVID-19 [3]. The comparison revealed that the functional outcomes and mortality rates in the patients with COVID-19 were worse than in those without COVID-19. In another new study, Merkl and co-workers presented data implying that patients with COVID-19 have a greater risk of acute ischemic stroke than patients with influenza [4]. Although the baseline stroke risk factors were more common in the COVID-19 cohort, this difference did not explain the higher risk of ischemic stroke associated with COVID-19, thus highlighting the need to identify COVID-19-specific factors.

2. COVID-19 and endothelial dysfunction

The authors of the latter comparative study [4] emphasized that inflammation, prothrombotic coagulopathy, and endothelial injury could have explained the increase in ischemic stroke in the COVID-19 patients. Indeed, in severe COVID-19, the virus also infects endothelial cells, and the high levels of circulating proinflammatory cytokines cause inflammatory damage to the vascular endothelium of the entire vascular tree, i.e., both at the macrovascular and microvascular level in various organs [5]. The damaged endothelial cells lose their anticoagulant surface properties, or they may die and expose the procoagulant subendothelial tissue, and in both cases, a local thrombus quickly develops.

3. COVID-19 patients with familial hypercholesterolemia and the risk of ischemic stroke

We wish to introduce here that a long-term pre-existing endothelial dysfunction may predispose to the development of vascular injury in COVID-19 patients. A notable subgroup of patients with a permanent pre-existing systemic endothelial dysfunction consists of those with untreated FH. Patients with FH (estimated prevalence 1 in 250, corresponding to approximately 30 million patients worldwide) have highly elevated serum low-density lipoprotein cholesterol (LDL-C) levels since birth, and correspondingly, endothelial dysfunction that develops already in childhood. Such endothelial dysfunction can be restored by statin treatment, and if left untreated, it increases cardiovascular risk later in life [6]. The FH-dependent endothelial dysfunction is present at the arterial and microcirculatory levels [11,12]. Notably, untreated adult patients with FH are known to have an increased risk of premature

Keywords: COVID-19, endothelial dysfunction, familial hypercholesterolemia, LDL cholesterol, stroke, statins

ARTICLE INFO

ABSTRACT

There is a continuing need for research about the underlying mechanisms behind ischemic strokes in COVID-19 patients. Pre-existing endothelial dysfunction, especially if it is accompanied by a viral infection of the endothelial cells may present an important mechanism behind the immunothrombotic/thromboembolic complications of the COVID-19 illness. Here we emphasize that pharmacotherapy with statins could partly counteract such pathophysiological scenarios. Accordingly, using familial hypercholesterolemia (FH) as a pertinent example of a lifelong endothelial dysfunction, we aim to make the clinicians and consulting neurologists aware of statins as a possible adjuvant therapy in the context of an increased risk of ischemic stroke in patients with COVID-19. Based on recent clinical evidence, there is a need to encourage clinicians and consulting neurologists to continue or initiate effective statin treatment to prevent an ischemic stroke, particularly when they encounter a hypercholesterolemic COVID-19 patient with FH.
myocardial infarction and ischemic brain infarction. Thus, before the statin era, the FH patients were found to have approximately a 20-fold increased risk for ischemic stroke, whereas later in the statin era, no increased risk for ischemic brain lesions was observed in statin-treated FH patients [13,14]. Since effective statin treatment normalizes endothelial function, we propose that the ability of statins to stabilize the vulnerable endothelial surfaces of unstable atherosclerotic plaques in cerebrovascular arteries is one of the mechanisms underlying the observed risk reduction in the statin-treated FH-patients.

4. Concluding remarks

In the study by Merkler et al. [4], the COVID-19 patients suffering from an acute ischemic stroke had significantly elevated levels of serum D-dimer revealing an activated coagulation system. In other studies, statin use has been found to associate with a modest decrease in the D-dimer levels, thereby revealing that statins may also act as mild anticoagulants [15]. It is then quite conceivable that statins have improved the prognosis among the hospitalized COVID-19 patients due to their endothelium-stabilizing and anticoagulant effects [16]. Accordingly, we are proposing that, based on individual considerations, clinicians treating COVID-19 patients initiate/continue or even intensify statin treatment in the context of stroke prevention in FH patients and also in other patients with severe hypercholesterolemia. This recommendation is highly relevant against the background that a significant fraction of FH patients uses statins either irregularly, at too low a dose, or not at all [17–19]. So, clinicians need to take care that hospitalized FH patients with COVID-19 reach the treatment goals for LDL-C, which usually requires a high-efficiency combined lipid-lowering therapy that includes a high dose of a high-intensity statin. The urgent call for continuing statin treatment in the hospital extends to all COVID-19 patients on statin therapy when hospitalized. Thus, as shown in the large observational, retrospective multicenter semi-COVID-19 Network study in Spain, more than half (1791/2921) of hospitalized COVID-19 patients receiving statin treatment had been discontinued from statin therapy during the hospitalization [20]. Of note, the authors found that the COVID-19 patients maintained on chronic statin therapy during the hospitalization had a lower mortality rate than those in whom statin therapy was withdrawn.

In addition to an elevated LDL-C level, FH patients have, on average, also higher levels of the highly proinflammatory and thrombogenic LDL-like lipoprotein particles, the lipoprotein(a) (Lp(a)) since birth [21]. Quite alarming, an elevated Lp(a) level likely increases the risk of ischemic stroke risk especially in COVID-19 patients [22]. Unfortunately, the statins do not usually lower the level of plasma Lp(a); instead, they may even slightly increase it [23]. Since our treatment goal is to reduce endothelial dysfunction in an FH patient with COVID-19, besides maintaining a low level of serum LDL-C, a markedly increased Lp(a) level should also be lowered [24]. In an FH patient, this may be achieved by adding to the combined high-efficiency lipid-lowering therapy (statin and ezetimibe) a PCSK9 inhibitor, which will further lower LDL-C by about 60%, and also lower Lp(a) by approximately 30% [21,24]. Additionally, the potential benefits of adding a PCSK9 inhibitor to the lipid-lowering regimen may also improve the cellular antiviral defense in a COVID-19 patient [25].

Currently, the data and expert opinions regarding any amenable effect of statins in hospitalized COVID-19 patients are based on observational retrospective studies and meta-analyses, and the consensus is that lipid-lowering drugs are generally safe in patients with coronavirus infections and should be continued [20,25–28]. In observational studies, reductions in the risk of severe illness and mortality due to COVID-19 among statin users have been studied. However, no comparable information exists regarding the effect of statin use on the risk of stroke. To test the hypothesis that statins, either alone or as a component of a lipid-lowering regimen, will mitigate the risk of ischemic stroke in hospitalized FH-patients with COVID-19, a large multinational and multi-ethnic registry study needs to be performed.

Financial disclosures

None.

Source of funding

None.

Author contribution

AV, PTH: writing the first draft and editing to produce the final draft; MK reviewing the final draft.

Declaration of competing interest

AV, MK none. PTK has received lecture honoraria and/or travel fees from Amgen, Novartis, Raisio Group, and Sanofi.

References

[1] Z. Iqbal, J.H. Ho, S. Adam, et al., Managing hyperlipidemia in patients with COVID-19 and during its pandemic: an expert panel position statement from HEART UK. Atherosclerosis 313 (2020) 126–136.
[2] A. Vuorio, F. Raal, M. Kaste, P.T. Kovanen, Familial hypercholesterolaemia and COVID-19: a two-hit scenario for endothelial dysfunction amenable to treatment. Atherosclerosis 320 (2021) 53–60.
[3] G. Ntados, P. Michel, G. Georgiopoulou, et al., Characteristics and outcomes in patients with COVID-19 and acute ischemic stroke. The Global COVID-19 Stroke Registry, Stroke 51 (2020) e254–e258.
[4] A.E. Merkler, N.S. Parikh, S. Mir, et al., Risk of ischemic stroke in patients with coronavirus disease 2019 (COVID-19) vs patients with influenza, JAMA Neurol. 77 (2020) 1–7.
[5] Z. Varga, A.J. Flammer, P. Steiger, et al., Endothelial cell infection and endotheliitis in COVID-19, Lancet 395 (2020) 1417–1418.
[6] R. Beyroutti, M.E. Adams, L. Benjamín, et al., Characteristics of ischaemic stroke associated with COVID-19. J. Neurol. Neurosurg. Psychiatry 91 (2020) 889–891.
[7] T.J. Oxley, J. Mocco, S. Majidi, et al., Large-vessel stroke as a presenting feature of COVID-19 in the young. N. Engl. J. Med. 382 (2020), e60.
[8] J. Conklin, M.P. Frosh, S.S. Mukerji, et al., Susceptibility-weighted imaging reveals cerebral microvascular injury in severe COVID-19, J. Neurol. Sci. 421 (2021) 117308.
[9] S. de Jongh, M.R. Lilien, J. op’t Roodt, E.S. Stroes, H.D. Bakker, J.J. Kastelein, Early statin therapy restores endothelial function in children with familial hypercholesterolaemia, J. Am. Coll. Cardiol. 40 (2002) 2117–2121.
[10] A. Vuorio, P.T. Kovanen, Prevention of endothelial dysfunction and thrombotic events in COVID-19 patients with familial hypercholesterolaemia, J. Clin. Lipidol. 14 (2020) 617–618.
[11] O. Schlager, K. Widhalm, A. Hammer, A. Giurgea, C. Margeta, M. Frisch, S. Zehetmayer, R. Koppensteiner, M.E. Gschwandtner, A. Willi-Erfahr-Hering, Familial hypercholesterolaemia affects microvascular autoregulation in children, Metabolism 62 (2013) 820–827.
[12] M. Kaste, P. Kovisto, Risk of brain infarction in familial hypercholesterolaemia, Stroke 19 (1988) 1097–1100.
[13] S. Soljanlahti, T. Autti, K. Lauerma, et al., Familial hypercholesterolaemia patients treated with statins at no increased risk for intracranial vascular lesions despite increased cholesterol burden and extracranial atherosclerosis, Stroke 36 (2005) 1572–1574.
[14] A. Undas, K.E. Brummell-Ziedins, K.G. Mann, Anticoagulant effects of statins and their clinical implications, Thromb. Haemost. 111 (2014) 392–400.
[15] M.R. Mehra, S.S. Desai, S.R. Kuy, T.D. Henry, A.N. Patel, Cardiovascular disease, drug therapy, and mortality in COVID-19, N. Engl. J. Med. 382 (2020), e102.
[16] J. Stock, First insights from the EAS familial hypercholesterolaemia collaboration registry. FH is still underdiagnosed and undertreated, Atherosclerosis 290 (2019) 138–139.
[17] J. Pang, D.R. Sullivan, D.L. Hare, et al., Gaps in the care of familial hypercholesterolaemia in Australia: first report from the National Registry, Heart Lung Circ. 2021 (30) (2021) 372–379.
[18] S. Yaman, D. Ozdemir, B.T. Akman, B. Cakir, O. Ersoy, Awareness, treatment rates, and compliance to treatment in patients with serum LDL cholesterol higher than 250 mg/dl, and possible, probable, or definite familial hypercholesterolaemia, Postgrad. Med. 153 (2021) 146–151.
[19] Torres-Peña JD, Pérez-Belmonte LM, Fuentes-Jiménez F, et al. Prior treatment with statins is associated with improved outcomes of patients with COVID-19: data from the SEMI-COVID-19 Registry [published online ahead of print, 2021 Mar 29]. Drugs.
Letter to the Editor

A. Vuorio, G.F. Watts, W.J. Schneider, S. Tsimikas, P.T. Kovanen, Familial hypercholesterolemia and elevated lipoprotein(a): double heritable risk and new therapeutic opportunities, J. Intern. Med. 287 (2020) 2–18.

P.M. Moriarty, L.K. Gorby, E.S. Stroes, J.P. Kastelein, M. Davidson, S. Tsimikas, Lipoprotein(a) and its potential association with thrombosis and inflammation in COVID-19: a testable hypothesis, Curr. Atheroscler. Rep. 22 (2020) 48.

S. Tsimikas, P.L.S.M. Gordts, C. Nora, C. Yeang, J.L. Witztum, Statins and increases in Lp(a): an inconvenient truth that needs attention, Eur. Heart J. 41 (2020) 192–193.

A. Vuorio, G.F. Watts, P.T. Kovanen, Depicting new pharmacological strategies for familial hypercholesterolaemia involving lipoprotein (a), Eur. Heart J. 38 (2017) 3555–3559.

A. Vuorio, P.T. Kovanen, PCSK9 inhibitors for COVID-19: an opportunity to enhance the antiviral action of interferon in patients with hypercholesterolaemia [published online ahead of print, 2020 Nov 21], J Intern Med (2020), https://doi.org/10.1111/joim.13210.

A. Vuorio, P.T. Kovanen, Statins as adjuvant therapy for COVID-19 to calm the stormy immunothrombosis and beyond, Front. Pharmacol. 11 (2021) 579548.

C.S. Kow, S.S. Hasan, Meta-analysis of effect of statins in patients with COVID-19, Am. J. Cardiol. 134 (2020) 155–155.

M. Banach, P.E. Penson, Z. Fras, et al., Brief recommendations on the management of adult patients with familial hypercholesterolemia during the COVID-19 pandemic, Pharmacol. Res. 158 (2020) 104891.

Alpo Vuorio\textsuperscript{ab,},*, Markku Kaste\textsuperscript{cd}, Petri T. Kovanen\textsuperscript{e}

\textsuperscript{a} University of Helsinki, Department of Forensic Medicine, 00014 Helsinki, Finland
\textsuperscript{b} Meiläinen Airport Health Centre, 01530 Vantaa, Finland
\textsuperscript{c} Department of Neurosciences, University of Helsinki, Helsinki, Finland
\textsuperscript{d} Department of Neurology, Helsinki University Hospital, Helsinki, Finland
\textsuperscript{e} Wihuri Research Institute, Biomedicum Helsinki 1, 00290 Helsinki, Finland

* Corresponding author: Lentäjäntie 1 E, 01530 Vantaa, Finland.

E-mail address: alpo.vuorio@gmail.com (A. Vuorio).